Indian equity markets have faced a decline for four consecutive sessions, with the Nifty falling significantly. Various factors, including ...

From a technical perspective, the 23,000–23,100 zone remains an immediate resistance level for the Nifty, according to Ponmudi R, CEO of En...

At CPHI Milan, Indian pharma players are looking beyond traditional exports, using partnerships, licensing, CDMO, and differentiated produc...

Linux Laboratories has secured $70 million in equity funding from ChrysCapital and Tata Capital Healthcare Fund III. This investment involv...

Private equity firm ChrysCapital is set to acquire a significant stake in Linux Laboratories. This deal will see existing investor Tata Cap...

Indian stock markets closed lower on Monday, extending their losing streak for four weeks. Investor sentiment remained subdued due to risin...

Indian equity markets ended lower on August 31, responding to prevailing global economic dynamics. A modest decline in the Nifty50 index br...

Elara has initiated coverage on four pharmaceutical stocks, assigning Buy, Accumulate and Reduce ratings. Alkem Laboratories emerged as its...

Mankind Pharma's shares are in focus following a 16.5% YoY decline in Q3 net profit to Rs 385 crore, despite strong revenue growth of 24%. ...

Mankind Pharma's Q3 FY25 net profit declined 16% YoY to ₹385 crore despite a 24% revenue increase to ₹3,230 crore. Domestic revenues rose 1...

Mankind Pharma on Thursday said its consolidated net profit declined 16.5 per cent to Rs 384 crore in the third quarter ended December 31, ...

Mankind Pharma's shares surged by 6% after reporting a 29% rise in Q2 profits, reaching ₹658.88 crore. The company attributed this growth t...

Mankind Pharma witnessed a 29% surge in consolidated net profit, reaching Rs 658.88 crore in the second quarter, ending September 2024. Thi...

After initially cheering the deal, the stock market gave its thumbs-down to Mankind acquiring BSV at the premium valuations of eight times ...

Business: Unlike its peers, Mankind Pharma started in rural India and is now expanding to urban India. The company earns 97% of its revenue...

"We wish to become a multinational pharma company by tapping the foreign markets," Chairman and Founder RC Juneja said.

Mankind Pharma has launched an anti-diabetic product 'Dynaglipt' targeting the middle class and rural diabetic patients.